A polypeptide and its composition and use
By developing polypeptide fragments that can interfere with the interaction between Synaptophysin and VAMP2, inhibiting the formation of SNARE complexes, the problem of high or poor risk of inhibiting muscle contraction and reducing wrinkles in the prior art is solved, and effective muscle contraction inhibition and skin Improve the effect.
Patent Information
- Application Number
- CN202280029549.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-28
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-03-28
AI Technical Summary
The prior art has high or poor risk in inhibiting muscle contraction and reducing wrinkles, and lacks risk-free and effective compounds to interfere with synaptic neurotransmitter release, resulting in muscle contraction.
Developed polypeptide fragments derived from Synaptophysin interfere with the interaction of Synaptophysin with VAMP2, inhibit the formation of SNARE complexes and neurotransmitter release, and thus inhibit muscle contraction.
By inhibiting muscle contraction, improving wrinkles on the skin surface, reducing wrinkle depth, achieving wrinkle removal effects, and can be used to treat or care for conditions and skin aging caused by muscle contraction.
Smart Images

Figure CN117203217B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of medicine and cosmetic technology, and in particular to a polypeptide and its composition and use. Background Art
[0002] The most obvious sign of human skin aging is the formation of facial wrinkles. Over time, affected by factors such as aging, external environment, and genetic factors, the body's nerve activity is excessive, and the neurotransmitters that stimulate muscle fibers are uncontrolled and excessively released, thereby dragging the muscle tension of the skin inward, deepening the primary line on the skin surface and forming wrinkles. At the cellular level, fibroblasts that synthesize extracellular matrix and collagen located on the tension line can exert specific contractile properties related to striated muscle under the action of muscle contraction. The junction between nerves and striated muscles constitutes the neuromuscular plate, and upstream of it is the motor neuron afferent nerve pathway. It is known that the skin muscles of the face are under the control of motor nerve afferents, which release acetylcholine from synaptic vesicles and act on the acetylcholine receptors on the postsynaptic membrane to cause muscle contraction, leading to wrinkle formation.
[0003] The vesicle must fuse with the presynaptic membrane before it can complete the exocytosis process and release acetylcholine. Membrane fusion is mediated by the N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex. The SNARE complex is a four-helix bundle structure, composed of synaptic vesicle-associated membrane protein (VAMP2) located on the vesicle membrane, synaptic-associated protein (SNAP25) located on the presynaptic membrane, and syntaxin. SNARE promotes the fusion of vesicle membrane and presynaptic membrane and the release of neurotransmitters by changing conformation and releasing energy during polymerization, thereby participating in neuronal exocytosis and muscle contraction activities. Synaptophysin is a synaptic vesicle transmembrane glycoprotein that exists in the presynaptic vesicles of neurons and the neurosecretory granules of neuroendocrine cells, and plays an important role in the release of neurotransmitters. Synaptophysin can interact with VAMP2 and dissociate from VAMP2 before VAMP2 forms a SNARE complex with SNAP25 and Syntaxin, thereby regulating the formation of the SNARE complex, leading to reduced neurotransmitter release under high-frequency stimulation. Abnormal regulation of Synaptophysin can lead to abnormal neuronal exocytosis and muscle contraction disorders.
[0004] At present, people have discovered several methods for reducing and / or eliminating expression wrinkles by targeting the SNARE protein complex. For example, local injection of botulinum toxin A is used for wrinkle removal, face slimming, elimination of frown lines and crow's feet, etc., but there is a risk of inducing an immune response and causing loss of therapeutic effect; peptides derived from the amino and carboxyl domains of SNAP-25 in patents WO0064932, EP1180524B1 and EP2123673B1; peptides derived from Munc18 in WO2019166347. However, there is currently a lack of compounds that can inhibit muscle contraction in a manner similar to the effectiveness of botulinum toxin but without the risk. Therefore, there is still a need to find compounds with other mechanisms of action to inhibit neuronal exocytosis and interfere with synaptic neurotransmitter release to meet the growing demand for treating or caring for the skin. Summary of the invention
[0005] The inventors of the present application have found that polypeptide fragments derived from Synaptophysin can interfere with the interaction between Synaptophysin and VAMP2, and thus inhibit the formation of the SNARE complex and the release of neurotransmitters (preferably acetylcholine), thereby inhibiting muscle contraction. Therefore, they can be used to treat or care for conditions, disorders or diseases caused by muscle contraction, as well as to treat or care for the skin.
[0006] In view of this, the present application provides a peptide represented by formula (I), or a stereoisomer thereof, or a mixture of stereoisomers thereof, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof,
[0007] R1-X1-X2-X3-X4-X5-X6-X7-X8-R2(I)
[0008] In formula (I),
[0009] X1 is selected from: -Val-, -Ser-, -Trp-, -Met-, -Leu-, -Glu-, -Ala-, -Pro-, -Tyr- or -Thr-;
[0010] X2 is selected from: -Lys-, -Arg-, -His-, -Met-, -Ala-, -Leu-, -Asn-, -Trp-, -Thr-, -Pro-, -Gly-, -Phe-, -Asp-, -Ser- or -Cys-;
[0011] X3 is selected from: -Val-, -Gly-, -Leu-, -Pro-, -Met-, -Ala-, -Gln-, -Asp-, -Phe-, -Ser-, -Cys- or -Lys-;
[0012] X4 is selected from: -Gly-, -Leu-, -Pro-, -Ala-, -Phe-, -Val-, -Trp-, -Asn- or -Glu-;
[0013] X5 is selected from: -Phe-, -Trp-, -Tyr- or a bond;
[0014] X6 is selected from: -Gln-, -Leu-, -Ala-, -Val-, -Phe-, -Arg-, -Tyr-, -Gly-, or -Asn-;
[0015] X7 is selected from: -Lys-, -Arg-, -His- or a bond;
[0016] X8 is selected from: -Trp-, -Ala-, -Asp-, -Lys-, -Gly-, -Tyr-, -Met- or -Arg-;
[0017] R1 is selected from: H or R3-CO-, wherein R3 is selected from: substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl;
[0018] R2 is selected from: -NR4R5 or -OR4, wherein each R4 and R5 are independently selected from: H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl;
[0019] The alkyl group refers to a saturated aliphatic straight or branched chain alkyl group having 1 to 24 carbon atoms (optionally having 1 to 16 carbon atoms; optionally having 1 to 14 carbon atoms; optionally having 1 to 12 carbon atoms; optionally having 1, 2, 3, 4, 5, or 6 carbon atoms); and may be selected from: methyl, ethyl, isopropyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, 2-ethylhexyl, 2-methylbutyl, or 5-methylhexyl;
[0020] The alkenyl group refers to a straight or branched alkenyl group having 2-24 carbon atoms (optionally having 2-16 carbon atoms; optionally having 2-14 carbon atoms; optionally having 2-12 carbon atoms; optionally having 2, 3, 4, 5, or 6 carbon atoms); the alkenyl group has one or more carbon-carbon double bonds, optionally having 1, 2 or 3 conjugated or non-conjugated carbon-carbon double bonds; the alkenyl group is bonded to the rest of the molecule through a single bond; and can be selected from: vinyl, oleyl, or linoleyl;
[0021] Optionally, the substituents in the "substituted alkyl" and "substituted alkenyl" are selected from C1-C4 alkyl; hydroxyl; C1-C4 alkoxy; amino; C1-C4 aminoalkyl; C1-C4 carbonyloxy; C1-C4 oxycarbonyl; halogen (such as fluorine, chlorine, bromine, and iodine); cyano; nitro; azide; C1-C4 alkylsulfonyl; thiol; C1-C4 alkylthio; C6-C 30 Aryloxy such as phenoxy; -NR b (C=NR b )NR b R c , where R b and R c are independently selected from: H, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C 10 Cycloalkyl, C6-C 18 Aryl, C7-C 17 an aralkyl group, a heterocyclic group having three to ten members, or a protecting group for an amino group.
[0022] Further, R1 is selected from: H, acetyl, tert-butyryl, hexanoyl, 2-methylhexanoyl, octanoyl, decanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, oleoyl or linoleoyl;
[0023] wherein R1 is selected from H, acetyl, lauroyl, myristoyl or palmitoyl;
[0024] Optionally, R1 is H or acetyl.
[0025] Further, R4 and R5 are independently selected from: H, methyl, ethyl, hexyl, dodecyl or hexadecyl;
[0026] wherein R4 is H and R5 is selected from: H, methyl, ethyl, hexyl, dodecyl or hexadecyl;
[0027] Optionally, R2 is -OH or -NH2.
[0028] Further, X5 is a bond, and X7 is a bond.
[0029] Furthermore, the peptide represented by formula (I), or its stereoisomer, or its mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, is selected from the following peptides (1)-(48):
[0030] (1)H-Val-Lys-Val-Leu-Gln-Trp-OH;
[0031] (2)H-Val-Lys-Val-Leu-Gln-Trp-NH2;
[0032] (3)Ac-Val-Lys-Val-Leu-Gln-Trp-OH;
[0033] (4)Ac-Val-Lys-Val-Leu-Gln-Trp-NH2;
[0034] (5)H-Ser-Met-Gly-Ala-Leu-Ala-OH;
[0035] (6)H-Ser-Met-Gly-Ala-Leu-Ala-NH2;
[0036] (7)Ac-Ser-Met-Gly-Ala-Leu-Ala-OH;
[0037] (8)Ac-Ser-Met-Gly-Ala-Leu-Ala-NH2;
[0038] (9)Ac-Val-His-Pro-Leu-Gln-Trp-OH;
[0039] (10)Ac-Val-His-Pro-Leu-Gln-Trp-NH2;
[0040] (11)Ac-Ser-Arg-Leu-Pro-Leu-Trp-OH;
[0041] (12)Ac-Ser-Arg-Leu-Pro-Leu-Trp-NH2;
[0042] (13)Ac-Trp-Lys-Val-Pro-Gln-Ala-OH;
[0043] (14)Ac-Trp-Lys-Val-Pro-Gln-Ala-NH2;
[0044] (15)Ac-Val-Arg-Leu-Gly-Phe-Gln-His-Trp-OH;
[0045] (16)Ac-Val-Arg-Leu-Gly-Phe-Gln-His-Trp-NH2;
[0046] (17)Ac-Val-His-Pro-Leu-Phe-Gln-His-Trp-OH;
[0047] (18)Ac-Val-His-Pro-Leu-Phe-Gln-His-Trp-NH2;
[0048] (19)Ac-Val-Ala-Val-Leu-Phe-Gln-Arg-Trp-OH;
[0049] (20)Ac-Val-Ala-Val-Leu-Phe-Gln-Arg-Trp-NH2;
[0050] (21)Ac-Val-Met-Gly-Pro-Trp-Leu-Lys-Ala-OH;
[0051] (22)Ac-Val-Met-Gly-Pro-Trp-Leu-Lys-Ala-NH2;
[0052] (23)Ac-Val-Met-Ala-Pro-Tyr-Leu-Lys-Ala-OH;
[0053] (24)Ac-Val-Met-Ala-Pro-Tyr-Leu-Lys-Ala-NH2;
[0054] (25)Ac-Ser-Ala-Val-Pro-Trp-Leu-Arg-Trp-OH;
[0055] (26)Ac-Ser-Ala-Val-Pro-Trp-Leu-Arg-Trp-NH2;
[0056] (27)Ac-Ser-Met-Ala-Gly-Trp-Gln-His-Ala-OH;
[0057] (28)Ac-Ser-Met-Ala-Gly-Trp-Gln-His-Ala-NH2;
[0058] (29)H-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-OH;
[0059] (30)H-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH2;
[0060] (31)Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-OH;
[0061] (32)Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH2;
[0062] (33)H-Trp-Lys-Ala-Leu-Phe-Gln-Arg-Trp-OH;
[0063] (34)H-Trp-Lys-Gly-Pro-Tyr-Gln-Met-Trp-OH;
[0064] (35)Ac-Met-Leu-Leu-Leu-Ala-Asp-NH2;
[0065] (36)Ac-Val-Asn-Gln-Leu-Val-Ala-NH2;
[0066] (37)Ac-Met-Leu-Asp-Phe-Leu-Ala-NH2;
[0067] (38)Ac-Leu-Trp-Phe-Val-Phe-Lys-NH2;
[0068] (39)Ac-Glu-Thr-Gly-Trp-Ala-Ala-NH2;
[0069] (40)Ac-Ala-Pro-Phe-Leu-Arg-Ala-NH2;
[0070] (41)Ac-Pro-Gly-Asp-Ala-Tyr-Gly-NH2;
[0071] (42)Ac-Tyr-Gly-Asp-Ala-Gly-Tyr-NH2;
[0072] (43)Ac-Ser-Phe-Ser-Asn-Gln-Met-NH2;
[0073] (44)Ac-Val-Asp-Cys-Ala-Asn-Lys-NH2;
[0074] (45)Ac-Val-Phe-Ala-Phe-Leu-Tyr-NH2;
[0075] (46)Ac-Ser-Ser-Ala-Trp-Ala-Lys-NH2;
[0076] (47)Ac-Thr-Cys-Lys-Glu-Leu-Arg-NH2;
[0077] (48)Ac-Leu-Asn-Leu-Val-Leu-Trp-NH2。
[0078] Further, the peptide, or a stereoisomer thereof, or a mixture of stereoisomers thereof, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, is selected from Ac-Val-Lys-Val-Leu-Gln-Trp-NH2, Ac-Ser-Met-Gly-Ala-Leu-Ala-NH2 or Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH2.
[0079] The peptide shown in formula (I) of the present application can exist as a stereoisomer or a mixture of stereoisomers; for example, the amino acids contained therein can have a L-, D- configuration, or be racemic independently of each other. Therefore, it is possible to obtain isomeric mixtures and racemic mixtures or diastereomeric mixtures, or pure diastereomers or enantiomers, depending on the number of asymmetric carbons and what isomers or isomeric mixtures are present. The preferred structure of the peptide shown in formula (I) of the present application is a pure isomer, that is, an enantiomer or a diastereomer.
[0080] For example, when -Phe- is described herein, it should be understood that -Phe- is selected from -L-Phe-, -D-Phe-, or a mixture of the two, and is racemic or non-racemic. The preparation methods described in this document enable a person of ordinary skill in the art to obtain each stereoisomer of the peptide of the present application by selecting amino acids with the correct configuration.
[0081] The present application also includes all suitable isotopic variants of the peptides shown in formula (I). Isotopic variants of these peptides of the present application are understood here to refer to compounds in which at least one atom in the peptide of the present application is replaced by another atom of the same atomic number, but the atomic mass of the other atom is different from the atomic mass usually or mainly present in nature. Examples of isotopes that can be incorporated into the peptides of the present application are those of hydrogen, carbon, nitrogen, oxygen or sulfur, such as 2 H (deuterium), 3 H (tritium), 13 C. 14 C. 15 N. 17 O. 18 O. 33 S. 34 S. 35 S or 36 Certain isotopic variants of the peptides of the present application (particularly those into which one or more radioactive isotopes have been incorporated) may be useful, for example, to examine the mechanism of action or distribution of the active compound in vivo; due to the relatively simple preparation and detectability, especially with 3 H or 14Compounds labeled with C isotopes are suitable for this purpose. In addition, due to the stronger metabolic stability of the compound, the incorporation of an isotope (e.g., deuterium) can produce specific therapeutic benefits, such as an extension of the half-life in vivo or a reduction in the required active dose; therefore, in some cases, this modification of the peptide of the present application may also constitute a preferred embodiment of the present application. By methods known to those skilled in the art, such as by the methods further described below and the methods described in the examples, by using the respective reagents and / or the corresponding isotopic modifications of the starting material, isotopic variants of the peptide of the present application can be prepared.
[0082] In addition, the present application also includes prodrugs of the peptides of the present application. The term "prodrug" herein means such compounds: they themselves may be biologically active or inactive, but during their residence time in the body, they react (e.g., metabolize or hydrolyze) to generate the peptides of the present application.
[0083] The term "cosmetically acceptable salt or pharmaceutically acceptable salt" refers to a salt approved for use in animals, and more specifically in humans, including metal salts of the peptide shown in formula (I), the metal including, but not limited to: lithium, sodium, potassium, calcium, magnesium, manganese, copper, zinc or aluminum, etc.; including salts formed by the peptide shown in formula (I) and organic bases, the organic bases including: ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, arginine, lysine, histidine or piperazine; including salts formed by the peptide shown in formula (I) and inorganic acids or organic acids, the organic acids including, but not limited to: acetic acid, citric acid, lactic acid, malonic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, aspartic acid, glutamic acid, succinic acid, oleic acid, trifluoroacetic acid, oxalic acid, pamoate or gluconic acid, etc.; the inorganic acids including, but not limited to: hydrochloric acid, sulfuric acid, boric acid or carbonic acid.
[0084] The synthesis of the peptide represented by formula (I) of the present application, or its stereoisomers or its cosmetically acceptable salts, or its pharmaceutically acceptable salts can be carried out according to conventional methods known in the prior art, such as solid phase synthesis, liquid phase synthesis or a combination of solid phase and liquid phase, and can also be prepared by biotechnology methods aimed at producing the desired sequence, or by controlled hydrolysis of proteins having animal, fungal, or plant origin.
[0085] For example, a method for obtaining a peptide represented by formula (I) comprises the following steps:
[0086] - coupling an amino acid having a protected N-terminus and a free C-terminus with an amino acid having a free N-terminus and a C-terminus that is protected or bound to a solid support;
[0087] - Elimination of the group protecting the N-terminus;
[0088] - repeating this coupling sequence and eliminating the group protecting the N-terminus until the desired peptide sequence is obtained;
[0089] - Elimination of the group protecting the C-terminus or cleavage from the solid support.
[0090] Preferably, the C-terminus is bound to a solid support and the method is carried out on a solid phase, comprising coupling an amino acid having a protected N-terminus and a free C-terminus with an amino acid having a free N-terminus and a C-terminus bound to a polymer support; eliminating the group protecting the N-terminus; and repeating this sequence as many times as required in order to thereby obtain a peptide of the desired length, followed by cleavage of the synthesized peptide from the initial polymer support.
[0091] The functional groups of the amino acid side chains remain fully protected with temporary or permanent protecting groups throughout the synthesis and can be deprotected simultaneously or orthogonally to the process of cleavage of the peptide from the polymer support.
[0092] Alternatively, solid phase synthesis can be performed by a convergent strategy of coupling the dipeptide or tripeptide to a polymer support or to a dipeptide or amino acid previously bound to a polymer support.
[0093] The functional groups at the terminals may be modified by deprotecting the N-terminus and C-terminus and / or cleaving the peptide from the polymer support in an undefined order using standard conditions and methods known in the art. The optional modification of the N-terminus and C-terminus may be performed on the peptide of formula (I) bound to the polymer support, or after the peptide has been cleaved from the polymer support.
[0094] Another aspect of the present application provides a cosmetic or pharmaceutical composition, comprising an effective amount of the peptide represented by the above formula (I), or its stereoisomers, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, and at least one excipient and optionally a cosmetically or pharmaceutically acceptable adjuvant.
[0095] Specifically, the adjuvant is selected from: collagen synthesis stimulators, agents that regulate PGC-1α synthesis, agents that regulate the activity of PPARγ, agents that increase or decrease the triglyceride content of adipocytes, agents that stimulate or delay adipocyte differentiation, lipolytic agents or agents that stimulate fat decomposition, lipolytic agents, lipogenic agents, inhibitors of acetylcholine receptor aggregation, agents that inhibit muscle contraction, anticholinergic agents, elastase inhibitors, matrix metalloproteinase inhibitors, melanin synthesis stimulators or inhibitors, whitening agents or depigmenting agents, pigmentation promoting agents, self-tanning agents, anti-aging agents, NO-synthase inhibitors, 5α-reductase inhibitors, inhibitors of lysyl hydroxylase and / or prolyl hydroxylase, antioxidants, free radical scavengers and / or anti-atmospheric pollution agents, Reactive carbonyl scavengers, anti-glycation agents, antihistamines, antivirals, antiparasitic agents, emulsifiers, emollients, organic solvents, liquid propellants, skin conditioning agents, moisturizers, moisture retaining substances, alpha hydroxy acids, beta hydroxy acids, moisturizers, epidermal hydrolases, vitamins, amino acids, proteins, pigments or colorants, dyes, biopolymers, gelling polymers, thickeners, surfactants, softeners, adhesives, preservatives, anti-wrinkle agents, agents capable of reducing or treating under-eye bags, exfoliants, keratolytic agents, keratolytic agents, antimicrobial agents, antifungal agents, antifungal agents, bacteriostatic agents, bacteriostatic agents, agents that stimulate the synthesis of dermal or epidermal macromolecules and / or are capable of inhibiting or preventing their degradation, agents that stimulate elastin synthesis, stimulating agents that stimulate the synthesis of decorin, agents that stimulate the synthesis of laminin, agents that stimulate the synthesis of defensins, agents that stimulate the synthesis of chaperone proteins, agents that stimulate the synthesis of cAMP, heat shock proteins, agents that stimulate the synthesis of HSP70, agents that stimulate the synthesis of heat shock proteins, agents that stimulate the synthesis of hyaluronic acid, agents that stimulate the synthesis of fibronectin, agents that stimulate the synthesis of sirtuins, agents that stimulate the synthesis of lipids and stratum corneum components, ceramides, fatty acids, agents that inhibit collagen degradation, agents that inhibit elastin degradation, agents that inhibit serine proteases, agents that stimulate fibroblast proliferation, agents that stimulate keratinocyte proliferation, agents that stimulate adipocyte proliferation, agents that stimulate melanocyte proliferation, agents that stimulate keratinocyte differentiation, agents that inhibit acetylcholinesterase, skin skin relaxants, agents that stimulate glycosaminoglycan synthesis, anti-hyperkeratotic agents, comedolytic agents, anti-psoriatic agents, anti-dermatitis agents, anti-eczema agents, DNA repair agents, DNA protective agents, stabilizers, antipruritic agents, agents for treating and / or caring for sensitive skin, firming agents, firming agents, reconstructing agents, anti-stretch mark agents, adhesives, agents for regulating sebum production, antiperspirants, agents that stimulate healing, agents that assist healing, agents that stimulate re-epithelialization, agents that assist re-epithelialization, cytokine growth factors, sedatives, anti-inflammatory agents, anesthetics, agents that act on capillary circulation and / or microcirculation, agents that stimulate angiogenesis, agents that inhibit vascular permeability, venous tension agents, agents that act on cell metabolism, agents for improving dermal-epidermal junction, agents that induce hair growth,Hair growth inhibiting or retarding agents, fragrances, chelating agents, plant extracts, essential oils, marine extracts, agents obtained from biological fermentation processes, inorganic salts, cell extracts, sunscreens, and organic or inorganic photoprotective agents effective against A and / or B ultraviolet rays, or mixtures thereof.
[0096] Further, the formulation of the cosmetic or pharmaceutical composition is selected from the group consisting of: cream, oil, milk, balm, foam, lotion, gel, liniment, serum, soap, shampoo, conditioner, serum, ointment, mousse, pomade, powder, stick, pen, spray, aerosol, capsule, tablet, granule, chewing gum, solution, suspension, emulsion, syrup, elixir, polysaccharide film, jelly or gelatin;
[0097] Specifically, the capsules include soft capsules, hard capsules, and gelatin capsules may be selected; the tablets include sugar-coated tablets.
[0098] The peptides of the present application have variable solubility in water, depending on the nature of their sequence or any possible modification in the N-terminus and / or C-terminus. Therefore, the peptides of the present application can be incorporated into the composition through an aqueous solution, and those that are insoluble in water can be dissolved in conventional solvents that are cosmetically or pharmaceutically acceptable, such as, but not limited to, ethanol, propanol, isopropanol, propylene glycol, glycerol, butylene glycol or polyethylene glycol, or any combination thereof.
[0099] The cosmetically or pharmaceutically effective amounts of the peptides of the present application to be administered, and their dosages, will depend on many factors, including the age, state of the patient, severity of the disorder or disease, route and frequency of administration, and the specific nature of the peptide to be used.
[0100] "A cosmetically or pharmaceutically effective amount" means an amount of one or more peptides of the present application that is non-toxic but sufficient to provide the desired effect. The peptides of the present application are used in a cosmetically or pharmaceutically effective concentration to obtain the desired effect in the cosmetic composition or pharmaceutical composition of the present application; in a preferred form, relative to the total weight of the composition, between 0.00000001% (by weight) and 20% (by weight), preferably between 0.000001% (by weight) and 15% (by weight), more preferably between 0.0001% (by weight) and 10% (by weight), and even more preferably between 0.0001% (by weight) and 5% (by weight).
[0101] In another aspect of the present application, a cosmetically or pharmaceutically acceptable delivery system or sustained-release system is provided to achieve better penetration of the active ingredient and / or improve its pharmacokinetic and pharmacodynamic properties, which comprises an effective amount of the peptide represented by the above formula (I), or its stereoisomers, or a mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, or the above cosmetic or pharmaceutical composition.
[0102] The term "delivery system" refers to a diluent, adjuvant, excipient or carrier used together with the peptide of the present application, which is selected from: water, oil or surfactant, including those of petroleum origin, animal origin, plant origin, or synthetic origin, such as and not limited to peanut oil, soybean oil, mineral oil, sesame oil, castor oil, polysorbate, sorbitan ester, ether sulfate, sulfate, betaine, glucosides, maltoside, fatty alcohol, nonoxynol ether, poloxamer, polyoxyethylene, polyethylene glycol, dextrose, glycerol, digitonin and the like. Those of ordinary skill in the art are known to diluents that can be used in different delivery systems that can administer the peptide of the present application.
[0103] The term "sustained release" is used in its conventional sense to refer to a delivery system that provides for gradual release of a compound over a period of time, and preferably, but not necessarily, with a relatively constant level of compound released over the entire period of time.
[0104] Examples of delivery systems or sustained release systems are liposomes, oleosomes, nonionic surfactant liposome vesicles, ethosomes, millicapsules, microcapsules, nanocapsules, nanostructured lipid carriers, sponges, cyclodextrins, lipid vesicles, micelles, millispheres, microspheres, nanospheres, lipid spheres, microemulsions, nanoemulsions, milliparticles, microparticles or nanoparticles. Preferred delivery systems or sustained release systems are liposomes and microemulsions, more preferably water-in-oil microemulsions with an internal structure of reverse micelles.
[0105] Sustained-release system can be prepared by methods known in the prior art, and can be given, for example, in the following manner: by topical or transdermal administration, including adhesive patch, non-adhesive patch, closure patch, and microelectronic patch; or by systemic administration, for example and not limited to, oral or parenteral route, including nose, rectum, subcutaneous implantation or injection or directly implanted or injected into a specific body part, and preferably these peptides of the present application of a relatively constant amount should be released. The amount of the peptide included in the sustained-release system will depend on the release kinetics and duration of the position, the peptide of the present application, and the condition to be treated and / or the property of nursing, illness and / or disease, for example, the composition will be given.
[0106] Another aspect of the present application provides a peptide represented by the above formula (I), or a stereoisomer thereof, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the above cosmetic or pharmaceutical composition, or the above cosmetically or pharmaceutically acceptable delivery system or sustained-release system for preparing a cosmetic composition or pharmaceutical composition for treating or caring for a condition, disorder or disease caused by muscle contraction, wherein the disorder or disease is dystonia.
[0107] In an embodiment of the present application, the disorder or disease is dystonia, specifically, the dystonia is focal dystonia; dystonia includes, but is not limited to facial spasm, torsion dystonia, cervical dystonia or torticollis, laryngeal dystonia or spasmodic dysphonia, oromandibular dystonia, limb dystonia such as writer's cramp or musician's cramp or foot dystonia, nocturnal bruxism, hemifacial spasm, tics and / or strabismus; segmental dystonia, Meige's syndrome, multifocal dystonia, hemidystonia, dopamine-responsive dystonia and Sekawa dystonia.
[0108] Another aspect of the present application provides a peptide represented by the above formula (I), or a stereoisomer thereof, or a mixture of stereoisomers, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or the above cosmetic or pharmaceutical composition, or the above cosmetically or pharmaceutically acceptable delivery system or sustained-release system for preparing a cosmetic composition or pharmaceutical composition for treating, preventing or repairing skin aging or photoaging, wherein the treatment, prevention or repair of skin aging or photoaging is the reduction, prevention or treatment of facial wrinkles.
[0109] In order to facilitate the understanding of this application, the meanings of some terms and expressions used in this application are explained as follows:
[0110] In the present application, the term "skin" is understood to mean the multiple layers that make it up, from the uppermost layer or stratum corneum to the lowermost layer or subcutaneous tissue, both ends are included. These layers are composed of different types of cells, such as keratinocytes, fibroblasts, melanocytes, and / or adipocytes, etc. In the present application, the term "skin" includes the scalp.
[0111] The term "treatment" refers to administering a peptide according to the present application to alleviate or eliminate a disease or condition, or to reduce or eliminate one or more symptoms associated with the disease or condition. The term "treatment" also encompasses the ability to alleviate or eliminate the physiological consequences of the disease or condition.
[0112] The term "care" includes the prevention of diseases and / or conditions.
[0113] The term "prevention" refers to the ability of the peptides of the present application to prevent, delay, or hinder the occurrence or development of a disease or condition before it occurs.
[0114] The term "aging" refers to the changes that the skin undergoes with age (natural aging) or through exposure to sunlight (photoaging) or to environmental pollutants, such as chemical dirt or pollution, tobacco smoke, etc., and includes all changes that are outwardly visible and / or perceptible by touch, such as and not limited to: the development of discontinuities in the skin (such as wrinkles, fine lines, expression lines, stretch lines, stripes, grooves, unevenness or roughness, increase in pore size, loss of moisture, loss of elasticity, loss of firmness, loss of smoothness, loss of deformation recovery ability, loss of resilience), sagging of the skin (such as sagging cheeks, bags under the eyes, or the appearance of a double chin, etc.), changes in skin color (such as scarring, redness, bags under the eyes, or the appearance of areas of hyperpigmentation such as age spots or freckles, etc.), abnormal differentiation, hyperkeratinization, elastosis, keratosis, hair loss, orange peel skin, loss of collagen structure, and other histological changes in the stratum corneum, dermis, epidermis, vascular system (such as the appearance of spider veins or telangiectasias) or those tissues close to the skin.
[0115] The term "photoaging" refers to the premature aging of the skin due to long-term exposure to ultraviolet radiation, which presents the same physiological characteristics as natural aging, such as but not limited to: loosening, sagging, color changes or irregular pigmentation, abnormalities and / or excessive keratinization.
[0116] In the present specification, the abbreviations used for amino acids follow the rules specified by the IUPAC-IUB Commission of Biochemical Nomenclature in the European Journal of Biochemistry (Eur. J. Biochem. 1984, 138: 9-37).
[0117] Thus, for example, Lys represents NH2-CH(CH2CH2CH2CH2NH2)-COOH, Lys- represents NH2-CH(CH2CH2CH2CH2NH2)-CO-, -Lys represents -NH-CH(CH2CH2CH2CH2NH2)-COOH, and -Lys- represents -NH-CH(CH2CH2CH2CH2NH2)-CO-. Thus, the hyphen representing a peptide bond eliminates the OH in the 1-carboxyl group of an amino acid (represented here in conventional non-ionized form) when located on the right side of the symbol, and eliminates the H in the 2-amino group of an amino acid when located on the left side of the symbol.
[0118] The abbreviation "Ac-" is used in this application to represent acetyl (CH3-CO-); Ser: serine; Gly: glycine; Ala: alanine; Lys: lysine; Trp: tryptophan; Val: valine; Leu: leucine; Gln: glutamine; Met: methionine; His: histidine; Arg: arginine; Pro: proline; Phe: phenylalanine; Tyr: tyrosine.
[0119] This application has the following advantages and effects:
[0120] The polypeptide of the present application is obtained through artificial design and is easy to synthesize. It regulates the formation of the SNARE complex by interacting with the synaptic vesicle-associated membrane protein (VAMP2), thereby interfering with the release of synaptic neurotransmitters, inhibiting muscle contraction, improving wrinkles on the skin surface, reducing the depth of wrinkles, and achieving a wrinkle removal effect. It can be used in the cosmetics or medical fields to improve skin aging or photoaging, and to treat or care for conditions, disorders or diseases caused by muscle contraction. BRIEF DESCRIPTION OF THE DRAWINGS
[0121] In order to more clearly illustrate the technical solution of the present application, the drawings required for use in the description of the present application will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0122] Figure 1 It is a peptide (4) Ac-Val-Lys-Val-Leu-Gln-Trp-NH2 (molecular formula C 40 H 64 N 10 O8) Mass spectrum, [M+H] + The mass-to-charge ratio (m / z) of the quasi-molecular ion peak was 813.5879, and the molecular weight measured by mass spectrometry was 812.59;
[0123] Figure 2 It is peptide (8) Ac-Ser-Met-Gly-Ala-Leu-Ala-NH2 (molecular formula C 24 H 43 N7O8S) mass spectrum, [M+Na] + The mass-to-charge ratio (m / z) of the summed ion peak was 612.3438, and the molecular weight measured by mass spectrometry was 589.34;
[0124] Figure 3 It is a peptide (32) Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH2 (molecular formula C 48 H 69 N13 O9) mass spectrum, [M+H] + The mass-to-charge ratio (m / z) of the quasi-molecular ion peak was 972.6496, and the molecular weight measured by mass spectrometry was 971.65;
[0125] Figure 4 This is the result of the muscle contraction inhibition experiment on the test sample. DETAILED DESCRIPTION
[0126] In order to make the objects, features and advantages of the present application more obvious and understandable, the present application is further described in detail below in conjunction with the accompanying drawings and embodiments. Obviously, the described embodiments are part of the embodiments of the present application, rather than all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present application.
[0127] The core concept of the present application is that a biomimetic peptide is obtained based on Synaptophysin, which can interfere with the interaction between Synaptophysin and VAMP2, and thus inhibit the formation of SNARE complex and neurotransmitter release, thereby inhibiting muscle contraction. The polypeptide has the following general formula: R1-X1-X2-X3-X4-X5-X6-X7-X8-R2; the peptide of the present application, its stereoisomer, mixture of stereoisomers, or its cosmetically acceptable salt, or its pharmaceutically acceptable salt, or its cosmetic composition or pharmaceutical composition, and their use in the preparation of cosmetic compositions or pharmaceutical compositions for improving skin aging or photoaging, treating or caring for conditions, disorders or diseases caused by muscle contraction.
[0128] It should be noted that, in the present application, the abbreviations used for amino acids follow the rules specified by the Biochemical Nomenclature Committee of IUPAC-IUB in Eur. J. Biochem. (1984) 138: 9-37 and J. Chem. (1989) 264: 633-673.
[0129] Amide Resin: a starting resin for peptide synthesis (cross-linking degree 1%, substitution degree 1.72mmol / g, particle size 100-200 mesh); Fmoc-Linker: 4-[(2,4-dimethoxyphenyl)(Fmoc-amino)methyl]phenoxyacetic acid; Ac2O: acetic anhydride; DMF: N,N-dimethylformamide; DIPEA: diisopropylethylamine; DIC: diisopropylcarbodiimide; piperidine: piperidine; HOBt: 1-hydroxybenzotriazole; TFA: trifluoroacetic acid; TIS: triisopropylamine Propylsilane; EDT: 1,2-ethanedithiol; Ser: serine; Gly: glycine; Ala: alanine; Lys: lysine; Trp: tryptophan; Val: valine; Leu: leucine; Gln: glutamine; Met: methionine; Arg: arginine; Pro: proline; Phe: phenylalanine; Fmoc: 9-fluorenylmethoxycarbonyl; Boc: tert-butoxycarbonyl; tBu: tert-butyl; Trt: trityl; Pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl.
[0130] Example 1 Computer simulation
[0131] In this experiment, computer simulation methods were used to screen candidate peptides that have affinity or specificity for the interaction region between Synaptophysin and VAMP2, and therefore can interfere with the interaction or binding between Synaptophysin and VAMP2, thereby affecting the formation of the SNARE complex.
[0132] First, the full sequence of Synaptophysin was used as the target protein, and amino acid residue fragments of different lengths were cut from it to construct overlapping peptide libraries with peptide chain lengths of 5, 6, 7 and 8 AAs. Since VAMP2 in the SNARE complex is a helical bundle structure, α-helic has an important influence on the affinity of the peptide with VAMP2, so the α-helic properties of the peptide were analyzed by computer.
[0133] According to the results of computer simulation of the α-helical properties of peptides, 27 peptides were initially screened out, as shown in Table 1 below.
[0134] Table 1 Peptides initially screened using computer simulation
[0135]
[0136]
[0137] In order to further evaluate the binding ability of peptides to VAMP2, VAMP2 before participating in the formation of SNARE complex was selected for study. Molecular docking and molecular dynamics were used to calculate the affinity of the above peptides to VAMP2, and then the best candidate peptides were screened and further activity verification was considered for them. The best candidate peptides are shown in Table 2 below.
[0138] Table 2 The best candidate peptides screened by computer simulation
[0139]
[0140] The results show that the peptide of the present application can bind well to VAMP2, thereby interfering with the formation of the SNARE complex and can be used to inhibit muscle contraction.
[0141] Example 2
[0142] Preparation of Ac-Val-Lys-Val-Leu-Gln-Trp-NH2
[0143] 2.1 Preparation of Fmoc-Linker-Amide Resin
[0144] Weigh 5 g of Amide Resin resin into a solid phase synthesis reaction column, swell it with DMF, wash the resin, and remove the solvent.
[0145] Weigh 7g of Fmoc-Linker and 2.10g of HOBt into a dry conical flask, dissolve them in DMF solvent, cool them in an ice-water bath for 10 minutes, and activate them with DIC for 10 minutes to avoid moisture.
[0146] The activated Fmoc-Linker was added to the swollen resin and reacted for 2.5 h. The reaction solution was removed, the resin was washed, and the solvent was removed.
[0147] Ac2O and DIPEA were added to cap the reaction mixture for 1.5 h. The resin was washed and the solvent was removed.
[0148] 2.2 Removal of Fmoc
[0149] Fmoc-Linker-Amide Resin was de-Fmoced twice with 20% piperidine / DMF, each time for 10 min, and samples were taken for K testing, showing dark blue color. The resin was washed with DMF for 7 times, and the solvent was removed.
[0150] 2.3 Feeding reaction
[0151] Weigh 5.3g of Fmoc-Trp(Boc)-OH and 1.8g of HOBt into a dry conical flask, add DMF to dissolve it, seal it and place it in a -18℃ refrigerator for 30min. Add 1.65g of DIC to activate for 3min, avoiding moisture. Add the activated amino acid to the deprotected resin and react for 2h, then remove the reaction liquid. The K test resin is colorless and transparent, indicating that the reaction is complete.
[0152] The N-terminal Fmoc group was deprotected, and 7.3 g of Fmoc-Gln(Trt)-OH after activation was coupled to the peptidyl resin using DMF as solvent in the presence of 1.8 g HOBt and 1.65 g DIC, and the reaction was continued for 2 h. The resins were then washed and the deprotection of the Fmoc group was repeated to couple the next amino acid. In each coupling, 4.2 g of Fmoc-Leu-OH; 4.0 g of Fmoc-Val-OH; 5.6 g of Fmoc-Lys(Boc)-OH and then 4.0 g of Fmoc-Val-OH were sequentially coupled in the presence of 1.8 g HOBt and 1.65 g DIC using DMF as solvent; after the reaction was complete, the resin was washed and the solvent was removed.
[0153] The N-terminal Fmoc group of the peptidyl resin was deprotected by using 20% piperidine / DMF for two times, each time for 10 min, and the sample was taken for K test, and the color was dark blue. The resin was washed with DMF for 6 times, and the solvent was removed.
[0154] In the presence of DIPEA, 1.9 g of Ac2O was coupled to the peptidyl resin using DMF as solvent. The reaction was continued for 1.5 h. The resin was washed, the solvent was removed, and the resin was shrunk and dried to obtain 12 g of Ac-Val-Lys(Boc)-Val-Leu-Gln(Trt)-Trp(Boc)-Linker-Amide Resin.
[0155] 2.4 Lysis
[0156] Measure 54 mL of TFA, 1.5 mL of TIS, 1.5 mL of EDT, 1.5 mL of thioanisole, and 1.5 mL of water, mix and stir evenly to obtain a cleavage solution, seal the container and place it in a -18°C refrigerator for later use; place isopropyl ether in a -18°C refrigerator for later use.
[0157] Weigh 12g of Ac-Val-Lys(Boc)-Val-Leu-Gln(Trt)-Trp(Boc)-Linker-Amide Resin, add it to a round-bottom flask, add the frozen lysate, and stir to react for 2h. Filter by suction, collect the filtrate, concentrate it to 10mL, add isopropyl ether, stir and centrifuge and wash 6 times until the pH value is 3-4, and vacuum dry to obtain 4.5g of Ac-Val-Lys-Val-Leu-Gln-Trp-NH2 crude peptide.
[0158] 2.5 Purification
[0159] Weigh 4.5 g of crude peptide and dissolve it in pure water. After concentration, add methanol to dissolve it completely. Filter with a microporous filter membrane with a pore size of 0.22 μm to obtain a clear and transparent solution. Purify it by reverse phase HPLC. The purification gradient is as follows:
[0160] Time (min) Flow rate (mL / min) A% (0.1% acetic acid + acetonitrile) B% (0.1% acetic acid + pure water) 0 40 10 90 15 40 30 70 50 40 45 55
[0161] The filtered sample was injected for purification, and the fractions were collected, concentrated and lyophilized to obtain peptide (4) Ac-Val-Lys-Val-Leu-Gln-Trp-NH2 with a purity of 98%.
[0162] Example 3
[0163] Preparation of Ac-Ser-Met-Gly-Ala-Leu-Ala-NH2
[0164] 3.1 Preparation of Fmoc-Linker-Amide Resin
[0165] Weigh 5 g of Amide Resin resin into a solid phase synthesis reaction column, swell it with DMF, wash the resin, and remove the solvent.
[0166] Weigh 6.9 g of Fmoc-Linker and 2.0 g of HOBt into a dry conical flask, dissolve them in DMF solvent, cool them in an ice-water bath for 10 min, and activate them with DIC for 10 min to avoid moisture.
[0167] The activated Fmoc-Linker was added to the swollen resin and reacted for 2.5 h. The reaction solution was removed, the resin was washed, and the solvent was removed.
[0168] Ac2O and DIPEA were added to cap the reaction mixture for 1.5 h. The resin was washed and the solvent was removed.
[0169] 3.2 Removal of Fmoc
[0170] Fmoc-Linker-Amide Resin was de-Fmoced twice with 20% piperidine / DMF, each time for 10 min, and samples were taken for K testing, showing dark blue color. The resin was washed 8 times with DMF, and the solvent was removed.
[0171] 3.3 Feeding reaction
[0172] Weigh 3.1g of Fmoc-Ala-OH and 1.8g of HOBt into a dry conical flask, add DMF to dissolve it, seal it and place it in a -18℃ refrigerator for 30min. Add 1.65g of DIC to activate it for 3min, avoiding moisture. Add the activated amino acid to the deprotected resin and react for 2h, then remove the reaction liquid. The K test resin is colorless and transparent, indicating that the reaction is complete.
[0173] The N-terminal Fmoc group was deprotected, and 4.2 g of Fmoc-Leu-OH after activation was coupled to the peptidyl resin using DMF as solvent in the presence of 1.8 g HOBt and 1.65 g DIC, and the reaction was continued for 2 h. The resins were then washed and the deprotection of the Fmoc group was repeated to couple the next amino acid. In each coupling, 3.1 g of Fmoc-Ala-OH; 3.6 g of Fmoc-Gly-OH; 4.5 g of Fmoc-Met-OH and then 4.6 g of Fmoc-Ser(tBu)-OH were sequentially coupled in the presence of 1.8 g HOBt and 1.65 g DIC using DMF as solvent; after the reaction was complete, the resin was washed and the solvent was removed.
[0174] The N-terminal Fmoc group of the peptidyl resin was deprotected by using 20% piperidine / DMF for two times, each time for 10 min, and the sample was taken for K test, and the color was dark blue. The resin was washed with DMF for 6 times, and the solvent was removed.
[0175] In the presence of DIPEA, 1.9 g of Ac2O was coupled to the peptidyl resin using DMF as solvent. The reaction was continued for 1.5 h. The resin was washed, the solvent was removed, and 13 g of Ac-Ser(tBu)-Met-Gly-Ala-Leu-Ala-Linker-Amide Resin was obtained after shrinkage and drying.
[0176] 3.4 Lysis
[0177] 44 mL of TFA, 1.2 mL of TIS, 1.2 mL of EDT, and 1.2 mL of water were measured and mixed and stirred evenly to obtain a cleavage solution, which was sealed and placed in a -18°C refrigerator for later use; isopropyl ether was placed in a -18°C refrigerator for later use.
[0178] Weigh 13g of Ac-Ser(tBu)-Met-Gly-Ala-Leu-Ala-Linker-Amide Resin, add it to a round-bottom flask, add the frozen lysate, and stir to react for 2h. Filter by suction, collect the filtrate, concentrate it to 10mL, add isopropyl ether, stir and centrifuge and wash 6 times until the pH value is 3-4, and vacuum dry to obtain 6.9g of Ac-Ser-Met-Gly-Ala-Leu-Ala-NH2 crude peptide.
[0179] 3.5 Purification
[0180] Weigh 6.9 g of crude peptide and dissolve it in 370 mL of pure water. Filter with a microporous filter membrane with a pore size of 0.22 μm to obtain a clear and transparent solution. Purify it by reverse phase HPLC. The purification gradient is as follows:
[0181] Time (min) Flow rate (mL / min) A% (0.1% acetic acid + acetonitrile) B% (0.1% acetic acid + pure water) 0 40 10 90 15 40 18 82 60 40 38 62
[0182] The filtered sample was injected for purification, and the fractions were collected, concentrated and lyophilized to obtain peptide (8) Ac-Ser-Met-Gly-Ala-Leu-Ala-NH2 with a purity of 99.4%.
[0183] Example 4
[0184] Preparation of Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH2
[0185] 4.1 Preparation of Fmoc-Linker-Amide Resin
[0186] Weigh 5 g of Amide Resin resin into a solid phase synthesis reaction column, swell it with DMF, wash the resin, and remove the solvent.
[0187] Weigh 6.9 g of Fmoc-Linker and 2.0 g of HOBt into a dry conical flask, dissolve them in DMF solvent, cool them in an ice-water bath for 10 min, and activate them with DIC for 10 min to avoid moisture.
[0188] The activated Fmoc-Linker was added to the swollen resin and reacted for 2.5 h. The reaction solution was removed, the resin was washed, and the solvent was removed.
[0189] Ac2O and DIPEA were added to cap the reaction mixture for 1.5 h. The resin was washed and the solvent was removed.
[0190] 4.2 Removal of Fmoc
[0191] Fmoc-Linker-Amide Resin was de-Fmoced twice with 20% piperidine / DMF, each time for 10 min, and samples were taken for K testing, showing dark blue color. The resin was washed with DMF for 7 times, and the solvent was removed.
[0192] 4.3 Feeding reaction
[0193] Weigh 3.1g of Fmoc-Ala-OH and 1.8g of HOBt into a dry conical flask. Add DMF to dissolve it, seal it and place it in a -18℃ refrigerator for 30min. Add 1.65g of DIC to activate it for 3min, avoiding moisture. Add the activated amino acid to the deprotected resin and react for 2h, then remove the reaction liquid. The K test resin is colorless and transparent, indicating that the reaction is complete.
[0194] The N-terminal Fmoc group was deprotected, and 7.6 g of Fmoc-Arg(Pbf)-OH after activation was coupled to the peptidyl resin using DMF as solvent in the presence of 1.8 g HOBt and 1.65 g DIC, and the reaction was continued for 2 h. The resins were then washed and the deprotection of the Fmoc group was repeated to couple the next amino acid. In each coupling, 4.2 g of Fmoc-Leu-OH; 5.3 g of Fmoc-Phe-OH; 4.62 g of Fmoc-Pro-OH; 4.26 g of Fmoc-Ala-OH; 4.26 g of Fmoc-Ala-OH and then 9.26 g of Fmoc-Trp(Boc)-OH were sequentially coupled in the presence of 1.8 g HOBt and 1.65 g DIC using DMF as solvent; after the reaction was complete, the resin was washed and the solvent was removed.
[0195] The N-terminal Fmoc group of the peptidyl resin was deprotected by using 20% piperidine / DMF for two times, each time for 10 min, and the sample was taken for K test, and the color was dark blue. The resin was washed with DMF for 6 times, and the solvent was removed.
[0196] In the presence of DIPEA, 1.9 g of Ac2O was coupled to the peptidyl resin using DMF as solvent. The reaction was continued for 1.5 h. The resin was washed, the solvent was removed, and the resin was shrunk and dried to obtain 20.3 g of Ac-Trp(Boc)-Ala-Ala-Pro-Phe-Leu-Arg(Pbf)-Ala-L inker-Amide Resin.
[0197] 4.4 Lysis
[0198] Measure 114 mL of TFA, 3 mL of TIS, and 3 mL of water, mix and stir evenly to obtain a cleavage solution, seal it and place it in a -18°C refrigerator for later use; place isopropyl ether in a -18°C refrigerator for later use.
[0199] Weigh 20.3g of Ac-Trp(Boc)-Ala-Ala-Pro-Phe-Leu-Arg(Pbf)-Ala-Linker-AmideResin, add it to a round-bottom flask, add the frozen lysate, and stir to react for 2h. Filter by suction, collect the filtrate and concentrate it to 10mL, then add isopropyl ether, stir and centrifuge and wash 6 times until the pH value is 3-4, and dry it in vacuum. 9.3g of Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH2 crude peptide is obtained.
[0200] 4.5 Purification
[0201] Weigh 9.3 g of crude peptide and dissolve it in 100 mL of methanol. Add 500 mL of pure water. After concentration, add 100 mL of methanol and filter with a microporous membrane with a pore size of 0.22 μm to obtain a clear and transparent solution. Purify it by reverse phase HPLC. The purification gradient is as follows:
[0202] Time (min) Flow rate (mL / min) A% (0.1% acetic acid + acetonitrile) B% (0.1% acetic acid + pure water) 0 40 20 80 15 40 30 70 50 40 45 55
[0203] The filtered sample was injected for purification, and the fractions were collected, concentrated and lyophilized to obtain peptide (32) Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH2 with a purity of 98%.
[0204] Example 5
[0205] Other compounds of formula (I) of the present application can be prepared by similar methods.
[0206] The molecular weights of the peptides obtained were determined by ESI-MS. The test results of some compounds are shown in Table 3 and Figure 1-3 :
[0207] Table 3 Molecular weight determination results by mass spectrometry
[0208]
[0209]
[0210] Example 6
[0211] Muscle contraction inhibition test
[0212] 6.1 Experimental Animals
[0213] Female SD rats, 10 weeks old, weighing 220 g to 260 g.
[0214] 6.2 Experimental Instruments
[0215] HW-400S constant temperature smooth muscle tank, BL-420E biofunction experimental system, tension transducer, and other instruments are conventional experimental instruments.
[0216] 6.3 Experimental reagents
[0217] Acetylcholine chloride (Shanghai Yuanye), chloral hydrate (Shanghai McLean)
[0218] 6.4 Samples to be tested
[0219] Acetyl octapeptide-3 (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2), tested at concentrations of 25ppm, 50ppm, 100ppm, and 200ppm;
[0220] Acetyl hexapeptide-30 (Ac-Glu-Asp-Tyr-Tyr-Arg-Leu-NH2), tested at concentrations of 25ppm, 50ppm, 100ppm, and 200ppm;
[0221] peptide (4), tested at concentrations of 25 ppm, 50 ppm, 100 ppm, and 200 ppm;
[0222] peptide (8), tested at concentrations of 25 ppm, 50 ppm, 100 ppm, and 200 ppm;
[0223] Peptide (32) was tested at concentrations of 100 ppm, 200 ppm, 400 ppm, and 800 ppm.
[0224] 6.5 Experimental methods
[0225] The experimental rats were fasted for 12 hours before the experiment. 10% chloral hydrate was injected intraperitoneally at a dose of 0.1mL / 25g. After the rats were anesthetized, the abdominal cavity was cut open to expose the enlarged cecum. A section of ileum was taken out from the ileocecal intestine and washed in a pre-oxygenated benchtop solution for 10 minutes. Several 4cm long sections of ileum were cut and incubated in a 4℃ benchtop solution for later use; the two ends of the ileum were partially ligated with cotton thread and tied to form a ring;
[0226] Turn on the HW-400S constant temperature smooth muscle tank and BL-420E biofunction experimental system, connect the tension transducer to channel 1, adjust the incubation temperature to 37°C, preheat the instrument for 0.5 hours, and ventilate for more than 10 minutes. Fix one end of the intestinal segment to the inlet bracket with cotton thread, and connect the other end to the tension transducer. Adjust the position and height of the transducer appropriately so that the isolated intestinal segment is placed in the center of the smooth muscle tank, and start recording intestinal activity;
[0227] After the muscle contraction stabilizes, add acetylcholine at a final concentration of 0.1-1μg / mL until the muscle activity shows a high and stable waveform, and act for 5 minutes as the initial control; after 5 minutes of equilibrium, add the samples to be tested. Each time a test drug is changed, a new ileum segment is replaced, and the instrument records the relevant data, and the ileum smooth muscle contraction inhibition rate is calculated according to the following formula:
[0228] Ileal smooth muscle contraction inhibition rate = (contractile force after acetylcholine administration - contractile force after test sample administration) / contractile force after acetylcholine administration × 100%
[0229] The experimental data were expressed as mean±SD.
[0230] 6.6 Experimental Results
[0231] The results of the ileum smooth muscle contraction inhibition rate of the test samples are shown in Table 4 and Figure 4 .
[0232] Table 4 Ileal smooth muscle contraction inhibition rate of test samples (%)
[0233]
[0234] The results showed that after administration of acetylcholine, a high signal peak was generated. After administration of acetyl hexapeptide-30 at 200ppm, the peak was significantly weakened, resulting in an inhibitory effect, with an inhibition rate of 48.09% at 200ppm. Administration of acetyl octapeptide-3 began to inhibit the high signal peak generated by acetylcholine at 50ppm, with an inhibition rate of 32.34% at 50ppm, 47.49% at 100ppm, and 58.67% at 200ppm. However, administration of peptide (4) and peptide (8) produced a significant inhibitory effect on the high signal peak generated by acetylcholine at 25ppm, and the inhibition rate decreased with the increase of the inhibitory effect. As the concentration increases, the inhibitory effect increases accordingly; peptide (4) produces an inhibitory effect at 25ppm, with an inhibition rate of 49.78%, an inhibition rate of 62.40% at 50ppm, an inhibition rate of 66.72% at 100ppm, and an inhibition rate of up to 76.88% at a concentration of 200ppm; the inhibition rate of peptide (8) is 31.99% at 25ppm, 34.35% at 50ppm, 56.42% at 100ppm, and an inhibition rate of up to 67.96% at a concentration of 200ppm; administration of peptide (32) produces an inhibitory effect on muscle contraction at 800ppm, with an inhibition rate of 44.41%.
[0235] It can be seen that the peptide of the present application has a significant effect of inhibiting muscle contraction, and is more potent than the peptide of the prior art; the inhibitory efficacy is peptide (4) > peptide (8) > acetyl octapeptide-3 > acetyl hexapeptide-30.
[0236] Inhibiting the contraction of facial expression muscles can effectively improve facial wrinkles such as eye wrinkles and nasolabial folds. As a neurotransmitter, acetylcholine can directly excite acetylcholine receptors on smooth muscle, triggering a signal cascade reaction and causing smooth muscle to produce a contraction effect. By inhibiting the release of cellular acetylcholine or preventing acetylcholine from binding to its receptor, muscle contraction can be inhibited, and conditions, disorders or diseases caused by muscle contraction can be treated or cared for, skin aging or photoaging can be treated, prevented or repaired, and facial wrinkles can be reduced, prevented or treated. The peptide of the present application interferes with the interaction between Synaptophysin and VAMP2, affects VAMP2 and SNAP25 and Syntaxin to form a SNARE complex, thereby inhibiting the release of acetylcholine, thereby inhibiting muscle contraction. This experiment further illustrates the technical effect of inhibiting muscle contraction of the peptide of the present application by detecting the ileal smooth muscle contraction signal and comparing the ileal smooth muscle contraction inhibition rate of each sample.
[0237] Example 7
[0238] Preparation of emulsion containing peptide (4)
[0239]
[0240]
[0241] Preparation method: prepare peptide (4) into a 0.02 mg / mL aqueous solution; heat cetearyl alcohol (and) cetearyl glucoside, jojoba oil, mineral oil, and isopropyl palmitate to 85°C and stir evenly to obtain phase A; dissolve glycerol, allantoin, polyacrylamide (and) C13-14 isoparaffin (and) laureth-7 in water and heat to 85°C to obtain phase B; quickly add phase A to phase B, homogenize at a constant temperature for 3-5 minutes, and cool; add a preservative when cooled to below 60°C, stir evenly, and add a polypeptide solution and flavor when cooled to below 45°C to obtain the product.
[0242] Example 8
[0243] Preparation of serum containing peptide (8)
[0244]
[0245] Preparation method: Add the prescribed amount of sodium hyaluronate into water, stir to mix evenly, then heat to 80-85°C, keep warm and stir to make it evenly dispersed; when the temperature drops below 40°C, add glycerin, aloe vera gel, peptide (8), vitamin C, caprylyl glycol and 1,2-hexanediol, stir evenly; adjust the pH value of the solution to about 5.5 with triethanolamine solution to obtain the product.
[0246] Although the preferred embodiments of the present application have been described, those skilled in the art may make additional changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the embodiments of the present application.
[0247] Finally, it should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or terminal device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or terminal device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or terminal device including the elements.
[0248] The above is a detailed introduction to a polypeptide and its cosmetic composition or pharmaceutical composition and use provided by the present application. Specific examples are used herein to illustrate the principle and implementation mode of the present application. The description of the above embodiments is only used to help understand the method and core idea of the present application. At the same time, for a person skilled in the art, according to the idea of the present application, there will be changes in the specific implementation mode and application scope. In summary, the content of this specification should not be understood as limiting the present application.
Claims
1. The following peptides (1) to (8), peptides (29) to (32), or cosmetically acceptable salts thereof, or pharmaceutically acceptable salts thereof: (1) H-Val-Lys-Val-Leu-Gln-Trp-OH; (2)H-Val-Lys-Val-Leu-Gln-Trp-NH 2 ; (3) Ac-Val-Lys-Val-Leu-Gln-Trp-OH; (4)Ac-Val-Lys-Val-Leu-Gln-Trp-NH 2 ; (5)H-Ser-Met-Gly-Ala-Leu-Ala-OH; (6)H-Ser-Met-Gly-Ala-Leu-Ala-NH 2 ; (7) Ac-Ser-Met-Gly-Ala-Leu-Ala-OH; (8)Ac-Ser-Met-Gly-Ala-Leu-Ala-NH 2 ; (29)H-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-OH; (30)H-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH 2 ; (31) Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-OH; (32)Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH 2 。 2. The peptide according to claim 1, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, It is characterized in that The peptide is selected from Ac-Val-Lys-Val-Leu-Gln-Trp-NH 2 ,Ac-Ser-Met-Gly-Ala-Leu-Ala-NH 2 or Ac-Trp-Ala-Ala-Pro-Phe-Leu-Arg-Ala-NH 2 .
3. The peptide according to claim 1 or 2, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, It is characterized in that The cosmetically acceptable salts or pharmaceutically acceptable salts include metal salts of the peptides, wherein the metal includes lithium, sodium, potassium, calcium, magnesium, manganese, copper, zinc or aluminum.
4. The peptide according to claim 1 or 2, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, It is characterized in that The cosmetically acceptable salt or pharmaceutically acceptable salt includes a salt formed by the peptide and an organic base, and the organic base includes ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, arginine, lysine, histidine or piperazine.
5. The peptide according to claim 1 or 2, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, It is characterized in that The cosmetically acceptable salt or pharmaceutically acceptable salt includes a salt formed by the peptide and an inorganic acid or an organic acid, wherein the organic acid includes acetic acid, citric acid, lactic acid, malonic acid, maleic acid, tartaric acid, fumaric acid, benzoic acid, aspartic acid, glutamic acid, succinic acid, oleic acid, trifluoroacetic acid, oxalic acid, pamoic acid or gluconic acid; the inorganic acid includes hydrochloric acid, sulfuric acid, boric acid or carbonic acid.
6. A cosmetic or pharmaceutical composition, It is characterized in that The composition comprises an effective amount of the peptide according to any one of claims 1 to 5, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, and at least one excipient and optionally a cosmetically or pharmaceutically acceptable adjuvant.
7. The cosmetic or pharmaceutical composition according to claim 6, It is characterized in that The adjuvant is selected from the group consisting of: collagen synthesis stimulators, agents that regulate PGC-1α synthesis, agents that regulate the activity of PPARγ, agents that increase or decrease the triglyceride content of adipocytes, agents that stimulate or delay adipocyte differentiation, lipolytic agents or agents that stimulate lipolysis, lipogenic agents, inhibitors of acetylcholine receptor aggregation, agents that inhibit muscle contraction, anticholinergic agents, elastase inhibitors, matrix metalloproteinase inhibitors, melanin synthesis stimulators or inhibitors, whitening agents or depigmenting agents, pigmentation promoting agents, self-tanning agents, NO-synthase inhibitors, 5α-reductase inhibitors, inhibitors of lysyl hydroxylase and / or prolyl hydroxylase, antioxidants, anti-vitamin B, anti-vitamin C, anti-vitamin D, anti-vitamin E, anti-vitamin F, anti-vitamin B, anti-vitamin B, anti-vitamin B, anti-vitamin C, anti-vitamin D agents that reduce or treat bags under the eyes, keratolytic agents, antimicrobial agents, agents that stimulate elastin synthesis, agents that stimulate decorin synthesis, agents that stimulate laminin synthesis, agents that stimulate defensin synthesis, agents that stimulate chaperone protein synthesis, agents that stimulate cAMP synthesis, agents that stimulate hyaluronic acid synthesis, agents that stimulate fibronectin synthesis agents that stimulate the synthesis of deacetylases, agents that stimulate the synthesis of lipids and stratum corneum components, ceramides, fatty acids, agents that inhibit collagen degradation, agents that inhibit elastin degradation, agents that inhibit serine proteases, agents that stimulate fibroblast proliferation, agents that stimulate keratinocyte proliferation, agents that stimulate adipocyte proliferation, agents that stimulate melanocyte proliferation, agents that stimulate keratinocyte differentiation, agents that inhibit acetylcholinesterase, skin relaxants, agents that stimulate glycosaminoglycan synthesis, anti-hyperkeratosis agents, comedolytic agents, anti-psoriatic agents, anti-eczema agents, DNA repair agents, DNA protective agents, stabilizers, antipruritic agents, firming agents, firming agents, restructuring agents, regulating agents Agents that regulate sebum production, antiperspirants, agents that stimulate healing, agents that assist healing, agents that stimulate re-epithelialization, agents that assist re-epithelialization, cytokines, sedatives, anti-inflammatory agents, anesthetics, agents that act on capillary circulation and / or microcirculation, agents that stimulate angiogenesis, agents that inhibit vascular permeability, agents that tone the veins, agents that act on cellular metabolism, agents for improving dermal-epidermal junctions, agents that induce hair growth, agents that inhibit or retard hair growth, fragrances, chelating agents, plant extracts, essential oils, marine extracts, agents obtained from biological fermentation processes, inorganic salts, cell extracts, and organic or inorganic photoprotective agents effective against A and / or B ultraviolet rays, or mixtures thereof.
8. The cosmetic or pharmaceutical composition according to claim 6 or 7, It is characterized in that The formulation of the cosmetic or pharmaceutical composition is selected from the group consisting of: cream, oil, balm, foam, lotion, gel, liniment, serum, ointment, mousse, powder, stick, pen, spray, aerosol, capsule, tablet, granule, suspension, emulsion, elixir, polysaccharide film or jelly.
9. The cosmetic or pharmaceutical composition according to claim 8, It is characterized in that The capsules include soft capsules and hard capsules.
10. The cosmetic or pharmaceutical composition according to claim 8, It is characterized in that The capsule is a gelatin capsule.
11. The cosmetic or pharmaceutical composition according to claim 8, It is characterized in that The tablets include: sugar-coated tablets.
12. A cosmetically or pharmaceutically acceptable delivery system or sustained release system, It is characterized in that A composition comprising an effective amount of a peptide according to any one of claims 1 to 5, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a cosmetic or pharmaceutical composition according to any one of claims 6 to 11; The cosmetically or pharmaceutically acceptable delivery system or sustained-release system is selected from the group consisting of liposomes, oleosomes, non-ionic surfactant liposome vesicles, ethosomes, millicapsules, microcapsules, nanocapsules, nanostructured lipid carriers, sponges, lipid vesicles, micelles, millispheres, microspheres, nanospheres, lipid spheres, microemulsions, nanoemulsions, milliparticles, microparticles or nanoparticles.
13. The cosmetically or pharmaceutically acceptable delivery system or sustained release system according to claim 12, It is characterized in that The cosmetically or pharmaceutically acceptable delivery system or sustained-release system is a liposome or a microemulsion.
14. The cosmetically or pharmaceutically acceptable delivery system or sustained-release system according to claim 12, It is characterized in that The cosmetically or pharmaceutically acceptable delivery system or sustained-release system is a water-in-oil microemulsion having an internal structure of reverse micelles.
15. Use of a peptide according to any one of claims 1 to 5, or a cosmetically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a cosmetic or pharmaceutical composition according to any one of claims 6 to 11, or a cosmetically or pharmaceutically acceptable delivery system or sustained-release system according to any one of claims 12 to 14 in the preparation of a cosmetic or pharmaceutical composition for treating, preventing or repairing skin aging or photoaging, in, The treatment, prevention or repair of skin aging or photoaging is the reduction, prevention or treatment of facial wrinkles.
Citation Information
Patent Citations
Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
EP1180524B1
Neuronal exocytosis inhibiting peptides
EP2123673B1
Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
WO2000064932A1
Peptides and compositions for use in cosmetics and medicine
WO2019166347A1
Abeta oligopeptide polymerization inhibitor and preparation and application thereof
CN102675419A
